Gulde Andrew, Zhang Shuyao, Hussain Iram
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
Division of Endocrinology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
J Emerg Med. 2023 Feb;64(2):200-207. doi: 10.1016/j.jemermed.2022.10.023. Epub 2023 Jan 27.
Patients presenting to the emergency department with paralysis can have a wide differential diagnosis. Thyrotoxic periodic paralysis (TPP) is a rare disorder causing transient flaccid paralysis in the setting of thyrotoxicosis and hypokalemia. It has been reported in Asian male populations predominantly, and the diagnosis is rarely considered in non-Asian populations. Recent research has identified cases in patients with diverse ethnic backgrounds, although epidemiologic data from the United States are very limited.
Our aim was to report our experience with TPP at a tertiary care center in the United States.
A retrospective chart review was conducted between January 2006 and February 2022 to identify cases of TPP and determine their demographic and clinical characteristics. Prevalence of TPP was estimated using the institutional hyperthyroidism registry.
Thirty-three patients with TPP were identified. All of the patients were male; median age was 28 years, and 85% were Hispanic. All patients had hypokalemia at presentation and 23% had rebound hyperkalemia after treatment. Prevalence of TPP in our population of patients with hyperthyroidism was approximately 0.5%.
Young Hispanic men presenting with paralysis should be evaluated for TPP, as the prevalence in this population may be higher than estimated previously. Management of TPP involves treatment of underlying hyperthyroidism and cautious potassium repletion, with an initial dose of no more than 60 mEq/L of potassium chloride to avoid rebound hyperkalemia.
因瘫痪就诊于急诊科的患者可能有多种鉴别诊断。甲状腺毒症性周期性瘫痪(TPP)是一种罕见的疾病,在甲状腺毒症和低钾血症的情况下导致短暂性弛缓性瘫痪。主要在亚洲男性人群中报道过,在非亚洲人群中很少考虑该诊断。最近的研究已经在不同种族背景的患者中发现了病例,尽管来自美国的流行病学数据非常有限。
我们的目的是报告我们在美国一家三级医疗中心治疗TPP的经验。
在2006年1月至2022年2月期间进行了一项回顾性病历审查,以确定TPP病例并确定其人口统计学和临床特征。使用机构甲状腺功能亢进登记处估计TPP的患病率。
确定了33例TPP患者。所有患者均为男性;中位年龄为28岁,85%为西班牙裔。所有患者就诊时均有低钾血症,23%在治疗后出现反弹性高钾血症。我们甲状腺功能亢进患者人群中TPP的患病率约为0.5%。
出现瘫痪的年轻西班牙裔男性应接受TPP评估,因为该人群中的患病率可能高于先前估计。TPP的管理包括治疗潜在的甲状腺功能亢进和谨慎补钾,初始剂量不超过60 mEq/L氯化钾以避免反弹性高钾血症。